An Open-Label, Multi-Center, Prospective, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery for Hypertrophic Scars in Healthy Adults

Trial Profile

An Open-Label, Multi-Center, Prospective, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery for Hypertrophic Scars in Healthy Adults

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 May 2017

At a glance

  • Drugs RXI 109 (Primary)
  • Indications Hypertrophic scars
  • Focus Therapeutic Use
  • Sponsors RXi Pharmaceuticals
  • Most Recent Events

    • 11 May 2017 According to a RXi Pharmaceuticals media release, the company will provide a full read-out, for Cohorts 3 and 4, in the second half of 2017.
    • 06 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Aug 2017.
    • 11 Aug 2016 According to a RXi Pharmaceuticals media release, company is evaluating the best treatment length (Cohorts 3 and 4) and anticipates preliminary data in the second half of 2016 with a full interim analysis, for Cohorts 3 and 4, mid-2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top